AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12173947
Drug: High-dose creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose creatine supplementation
Trial: 11093435
Drug: Intramuscular gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular gold sodium thiomalate (GSTM)
Trial: 11093435
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with double dose of RA linked alleles
Trial: 9098861
Drug: Insulin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (30 microU/mL)
Trial: 9098861
Drug: Insulin receptor
RxNorm normalized name: Insulin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin receptor mRNA expression
Trial: 25966916
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control vaccines
Trial: 19349552
Drug: Oral sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sorafenib 400 mg twice daily on days 2 to 19 plus intravenous paclitaxel 225 mg/m2 and intravenous carboplatin AUC 6 on day 1
Trial: 19349552
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus intravenous paclitaxel 225 mg/m2 and intravenous carboplatin AUC 6 on day 1
Trial: 11142539
Drug: MBT (M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBT (M plus behavioral coping skills therapy)
Trial: 9272298
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion for five consecutive days (7-hour infusion)
Trial: 9272298
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion for one day
Trial: 7525359
Drug: Oral danazol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral danazol, 50 mg/d for 9 months (group I, n = 21)
Trial: 7525359
Drug: Leuprolide depot
RxNorm normalized name: leuprolide acetate Injectable Suspension [Lupron Depot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide depot for 3 months followed by oral danazol, 50 mg/d for 6 months (group II, n = 21)
Trial: 21986980
Drug: Intravenous physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous physiological saline (control group)
Trial: 18728172
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at 33 microg/kg.d
Trial: 18728172
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy at 67 microg/kg.d
Trial: 14631268
Drug: Continuous hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous hormone therapy with rivastigmine (n=59)
Trial: 8087522
Drug: Chemotherapy (doxorubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (doxorubicin, etoposide, cyclophosphamide, plus methotrexate or cisplatin) and thoracic radiotherapy (total dose of 45, 55, 65 and 61 Gy)
Trial: 8087522
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and thoracic radiotherapy
Trial: 2669155
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25 mg plus triamterene (50 mg)
Trial: 782970
Drug: Spray device
RxNorm normalized name: AMPUL WITH PUMP SPRAY DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray device 1
Trial: 782970
Drug: Spray device
RxNorm normalized name: AMPUL WITH PUMP SPRAY DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray device 2
Trial: 782970
Drug: Spray device
RxNorm normalized name: AMPUL WITH PUMP SPRAY DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray device 3
Trial: 782970
Drug: Analgesics (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesics (for volunteers with fourfold or greater antibody response)
Trial: 782970
Drug: No analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesics (for volunteers with no serological response)
Trial: 28151459
Drug: 1 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/day Nigella sativa (NS-1)
Trial: 28151459
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day Nigella sativa (NS-2)
Trial: 12518490
Drug: Oral-B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B CrossAction (advanced-design manual toothbrush)
Trial: 12518490
Drug: Oral-B 40
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral-B 40 Indicator (flat-trimmed toothbrush)
Trial: 1958449
Drug: RG 12525
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG 12525 800 mg
Trial: 28464041
Drug: PopART intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PopART intervention (universal testing and treatment)
Trial: 10943876
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral methotrexate (MTX) 15 mg/m2 (increased to 20 mg/m2 after 2 months)
Trial: 1736617
Drug: Dofetilide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide (1 of 2 dose levels)
Trial: 1736617
Drug: Dofetilide (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide (high-dose level)
Trial: 31564933
Drug: PEDYPHAR ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEDYPHAR ointment
Trial: 31564933
Drug: Panthenol ointment
RxNorm normalized name: Panthenol
DrugBank: Panthenol (DB11204)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panthenol ointment (control)
Trial: 30594223
Drug: Incentive Scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive Scheme with motivational interviewing; gift vouchers of US$5.6 for VL < 20 copies/mL at 12 weeks, US$2.8 for VL suppression for the next 3 months, US$5.6 for VL < 20 copies/mL at 1 year.
Trial: 19917571
Drug: PI-88 in
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PI-88 in combination with docetaxel (75 mg/m2 every three weeks)
Trial: 10229064
Drug: Lorazepam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (6 mg/day)
Trial: 8912562
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol (0.5 to 2 micrograms daily)
Trial: 1819620
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g i.v. of imipenem‐cilastatin at induction of anesthesia
Trial: 1819620
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g i.v.) plus metronidazole (0.5 g i.v.) at the time of anesthesia and two other administrations of the combined antibiotics (cefuroxime 0.75 g plus metronidazole 0.5 g i.v.) every 8 hours
Trial: 6698566
Drug: Meptazinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (200 mg 3 hourly for 4 doses)
Trial: 6698566
Drug: Meptazinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (200 mg 3 hourly for 4 doses) + Ethanol (0.8 g/kg)
Trial: 26179814
Drug: Standard pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmaceutical care (control)
Trial: 8758193
Drug: Best conventional
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best conventional therapy
Trial: 30092411
Drug: Monotherapy (amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (amlodipine 10 mg od; lisinopril 20 mg od; chlorthalidone 25 mg od)
Trial: 30092411
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (amlodipine 5 mg od and lisinopril 20 mg od; amlodipine 5 mg od and chlorthalidone 25 mg od; lisinopril 20 mg od and chlorthalidone 25 mg od; amiloride 10 mg od and chlorthalidone 25 mg od)
Trial: 22907609
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg kg(‐1) bolus during induction, followed by 2 mg kg(‐1) h(‐1) intraoperative infusion and 1.3 mg kg(‐1) h(‐1) for 24 h postoperatively)
Trial: 12572373
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of methotrexate (MTX), sulfasalazine (SSZ) and Fengshi No. 1 (FS1)
Trial: 9440376
Drug: Lysine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine intake of 12 mg.kg‐1.d‐1
Trial: 9440376
Drug: Lysine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine intake of 28 mg.kg‐1.d‐1
Trial: 8595517
Drug: IL-1ra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-1ra (100 mg bolus followed by 2.0 mg/kg/h i.v. for 72 h)
Trial: 227571
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CCNA, methotrexate, and adriamycin in epidermoid carcinoma
Trial: 227571
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CCNU, cyclophosphamide, and methotrexate in adenocarcinoma
Trial: 227571
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclophosphamide and adriamycin
Trial: 227571
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CCNU, procarbazine, and 5-fluorouracil
Trial: 27461168
Drug: Sorghum bicolor
RxNorm normalized name: SORGHUM BICOLOR WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorghum bicolor extract (500 mg/d) + folic acid (5 mg/d) + iron (200 mg three times daily)
Trial: 27461168
Drug: Routine hematinics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine hematinics (folic acid 5 mg/d and iron 200 mg three times daily)
Trial: 23426033
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (600 mg/d)
Trial: 21768541
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplementation (40 g/d for 8 weeks)
Trial: 21768541
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein supplementation (40 g/d for 8 weeks)
Trial: 19961750
Drug: Mini-screw implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-screw implants
Trial: 10741813
Drug: Bupivacaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (5 ml of 0.25% bupivacaine at each incisional area, total of 20 ml)
Trial: 10741813
Drug: Control (physiologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (physiologic saline solution, total of 20 ml)
Trial: 1586367
Drug: Behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural therapy (exposure in vivo and response prevention)
Trial: 1586367
Drug: Behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural therapy followed by cognitive therapy
Trial: 1586367
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy followed by behavioural therapy
Trial: 24338242
Drug: Anesthesiologist-administered sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesiologist-administered sedation
Trial: 24338242
Drug: Nurse-administered propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered propofol sedation (NAPS) or endoscopist-directed sedation (EDS)
Trial: 23240152
Drug: Melatonin (melaxen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (melaxen, 1.5 mg, 2 weeks)
Trial: 20479445
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received nonsteroidal anti-inflammatory drugs, orthoses, and corticosteroid injections if needed)
Trial: 15230045
Drug: Trimetazidine 60
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 60 mg/day for 4 weeks
Trial: 11382726
Drug: GP IIb/IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP IIb/IIIa antagonist therapy with >/=95% platelet inhibition at 10 minutes after therapy initiation
Trial: 11382726
Drug: Platelet function
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet function inhibition <70% at 8 hours after therapy initiation
Trial: 11382726
Drug: Platelet function
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet function inhibition >/=95% at 10 minutes after therapy initiation
Trial: 8102894
Drug: Cefotaxime (Claforan)
RxNorm normalized name: cefotaxime Injection [Claforan]
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime (Claforan) 2 g intravenously at induction and 3 and 9 hours later (n = 280)
Trial: 8102894
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g plus metronidazole (Flagyl) 1.5 g intravenously at induction (n = 287)
Trial: 3111953
Drug: FOY (injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOY (injectable synthetic protease inhibitor)
Trial: 18467725
Drug: Initial adjuvant
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial adjuvant treatment with fluorouracil (FU)-based therapy
Trial: 8978020
Drug: Live varicella
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live varicella zoster virus (VZV) vaccine
Trial: 8978020
Drug: Killed varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed varicella zoster virus (VZV) vaccine
Trial: 6152344
Drug: Cholecystokinin-octapeptide (CCK-8)
RxNorm normalized name: Cholecystokinin C-terminal octapeptide
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cholecystokinin-octapeptide (CCK-8) 10 micrograms weekly intravenous injections
Trial: 21137167
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Urovaxom and Luivac combined with small doses of fluorochinolones over 12 months
Trial: 21137167
Drug: Long-term chemoprophylaxis
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term chemoprophylaxis with small doses of fluorochinolones
Trial: 15226323
Drug: Bicalutamide (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (150 mg by mouth daily)
Trial: 3264710
Drug: Aspirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (600 mg four times daily; 17 doses)
Trial: 3264710
Drug: Indomethacin BP
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin BP (50 mg three times daily; 13 doses)
Trial: 3264710
Drug: Indocid‐R (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indocid‐R (75 mg twice daily; 9 doses)
Trial: 3264710
Drug: Indomethacin Continus
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin Continus (75 mg twice daily; 9 doses)
Trial: 23514770
Drug: Multiple micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrient supplementation (MMS) with 5 mg of iron (ferrous sulfate) for 5 months
Trial: 20470276
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (50 mg) with N-acetylcysteine
Trial: 20470276
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (100 mg)
Trial: 20470276
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (50 mg)
Trial: 14736075
Drug: Inosiplex (Isoprinosine)
RxNorm normalized name: Inosiplex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosiplex (Isoprinosine) 100 mg/kg/day to a maximum of 3 g/day, taken orally in three divided doses for 6 months
Trial: 14736075
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of inosiplex and intraventricular interferon‐alpha2b (Intron A), starting with 100,000 U/m2 and escalating to 1,000,000 U/m2 over 5 inpatient days, then 1,000,000 U/m2 twice a week for 6 months
Trial: 10425809
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (25 mg/kg)
Trial: 2272191
Drug: Cronassial (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cronassial (100 mg in 2 ml buffered solution)
Trial: 6250769
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of Acyclovir (9‐(2‐hydroxyethoxymethyl)guanine)
Trial: 21860339
Drug: Nevirapine treatment
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine treatment in patients with different genotypes
Trial: 21860339
Drug: Nevirapine treatment
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine treatment in patients with CYP2B6 516G>T polymorphism
Trial: 21860339
Drug: Nevirapine treatment
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine treatment in patients with CYP2C19 8403AA genotype
Trial: 19387646
Drug: Methotrexate plus
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate plus TNF alpha antagonist
Trial: 19387646
Drug: Methotrexate (15–20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (15–20 mg weekly for 3 months)
Trial: 15480990
Drug: Recombinant coagulation
RxNorm normalized name: Recombinant coagulation factor IX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant coagulation factor VIIa (rFVIIa) 100 microg/kg, 8 doses
Trial: 3356847
Drug: Four different
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four different SR theophylline formulations
Trial: 28954098
Drug: Homologous platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous platelet gel
Trial: 21333984
Drug: Micronized vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized vaginal P gel
Trial: 21333984
Drug: Micronized P
RxNorm normalized name: Neo-Rx Micronized Powder for Compounding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized P capsule
Trial: 17499653
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine and epinephrine (TLE) using sequential layered application
Trial: 17499653
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine and epinephrine (TLE)
Trial: 12585303
Drug: Pharmaceutical pricing
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical pricing after the policy change regarding patient out-of-pocket expenses.
Trial: 9706049
Drug: Guar gum-based
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum-based diltiazem formulations
Trial: 2712549
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day amantadine
Trial: 2712549
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day amantadine
Trial: 2712549
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day amantadine
Trial: 29188864
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein intake (1.3 g/kg/day)
Trial: 29188864
Drug: Lower protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower protein intake (0.8 g/kg/day)
Trial: 23488545
Drug: H1-receptor antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H1-receptor antagonists